surmount-1 trial tirzepatide non-diabetic obesity weight loss For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The Nutritional status with tirzepatide in
Description
Keeping dinners light and avoiding eating close to bedtime improves both comfort and sleep quality
The GIP and GLP-1 receptor agonist tirzepatide is its active ingredient
Track symptoms daily so you can flag persistent constipation, severe nausea, or dizziness to your prescriber right away, and keep a log of food intake and strength workouts for muscle preservation
It is essential to recognize that while these medications are in the same family, their impact on the digestive system is not identical
doi: 10.1111/obr.13256
That doesnt make them any less frustrating or real
